| 0 (0%) | 10-15 12:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 53.24 | 1-year : | 62.19 |
| Resists | First : | 45.59 | Second : | 53.24 |
| Pivot price | 43  |
|||
| Supports | First : | 41.69 | Second : | 39.29 |
| MAs | MA(5) : | 43.72 |
MA(20) : | 42.38 |
| MA(100) : | 39.79 |
MA(250) : | 37.68 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 72.7 |
D(3) : | 70.6 |
| RSI | RSI(14): 61.8 |
|||
| 52-week | High : | 45.59 | Low : | 31.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GSK ] has closed below upper band by 37.4%. Bollinger Bands are 65.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.17 - 44.32 | 44.32 - 44.46 |
| Low: | 43.25 - 43.46 | 43.46 - 43.64 |
| Close: | 43.83 - 44.11 | 44.11 - 44.37 |
Wed, 15 Oct 2025
GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute - Fierce Pharma
Wed, 15 Oct 2025
GSK Executives Increase Shareholdings Through Dividend Reinvestment - TipRanks
Wed, 15 Oct 2025
GSK touts study showing acceptability edge for its long-acting PrEP drug amid Gilead showdown - Fierce Pharma
Wed, 15 Oct 2025
SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination - Quiver Quantitative
Wed, 15 Oct 2025
GSK chief doesn't buy that the CEO role has become unsustainable - Fortune
Wed, 15 Oct 2025
GSK CEO Emma Walmsley says it's ‘obnoxious’ when CEOs complain about their hard lives | Trending - Hindustan Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2,010 (M) |
| Shares Float | 3,910 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 19.1 (%) |
| Shares Short | 12,480 (K) |
| Shares Short P.Month | 11,140 (K) |
| EPS | 2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.65 |
| Profit Margin | 10.8 % |
| Operating Margin | 30.5 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 28.3 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 11.27 |
| Sales Per Share | 15.73 |
| EBITDA (p.s.) | 4.62 |
| Qtrly Earnings Growth | 23.2 % |
| Operating Cash Flow | 7,720 (M) |
| Levered Free Cash Flow | 5,480 (M) |
| PE Ratio | 19.72 |
| PEG Ratio | 0 |
| Price to Book value | 11.99 |
| Price to Sales | 2.78 |
| Price to Cash Flow | 11.39 |
| Dividend | 0.43 |
| Forward Dividend | 0 |
| Dividend Yield | 0.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|